Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor prognosis due to early metastasis, low diagnostic rates at early stages, and resistance to current therapeutic regimens. Despite numerous studies and clinical trials, the mortality rate for PDAC has shown limited improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Vahabi, Mahrou, Dehni, Bilal, Antomás, Inés, Giovannetti, Elisa, Peters, Godefridus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584721/
https://www.ncbi.nlm.nih.gov/pubmed/37490255
http://dx.doi.org/10.1007/s10555-023-10127-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584721/
https://www.ncbi.nlm.nih.gov/pubmed/37490255
http://dx.doi.org/10.1007/s10555-023-10127-w

Ejemplares similares